전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved71 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

atezolizumab (Tecentriq, TACE-HACI, plus atezolizumab-bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Recruiting
CGTLimited DatastaleShanghai GeneChem Co., Ltd.Phase 2

TAI-GPC3-CART cells (TAI-GPC3-CART cells)

Carcinoma, Hepatocellular · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleChugai PharmaceuticalPhase 1

Tocilicumab (Tocilicumab)

Hepatocellular Carcinoma (HCC) · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase1#monoclonal-antibody#Chugai
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#monoclonal-antibody#UnresectableHepatocellularCarcin+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab immunotherapy (Tremelimumab immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Recruiting
CGTLimited DatastaleBeijing 302 HospitalPhase 2

allogeneic NK cells therapy (allogeneic NK cells therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
CGTLimited DatastaleAeon Therapeutics (Shanghai) Co…Phase 1

autologous ET1402L1-CART cells (autologous ET1402L1-CART cells)

Hepatocellular Carcinoma; Liver Cancer · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

cTACE+Atirizumab+Bevacizumab (cTACE+Atirizumab+Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active

4 / 4 pages

← PreviousNext →